The Syngene International results for Q4 FY25 show a mixed outcome.
Net profit increased by 6% year-on-year to Rs 189 crore, despite an 8% revenue drop to Rs 917 crore.
The revenue decline stems from lower demand in the US biotech sector due to funding challenges.
However, the EBITDA margin improved to 36% from 33%, even as EBITDA fell 1% to Rs 333 crore.
The stock fell 10% to Rs 675.60 amid a cautious FY26 outlook.
Analysts suggest buying, with a target price of Rs 1030, indicating a 51.94% upside.
Read More at IndiaHood
